Stocks to Watch: Levi Strauss, Ocuphire Pharma, Magenta Therapeutics, Las Vegas Sands, Seagate Technology

Sabela Ojea

Levi Strauss & Co. said Wednesday that it expects revenue and earnings growth in 2023 after beating analysts expectations for the last quarter of 2022. Shares of the jeans marker gained 6.4% in after-hours trading.

Ocuphire Pharma Inc. said its APX3330 treatment for the diabetic retinopathy eye disease didn’t meet the primary endpoint in a recent study. Shares of the ophthalmic biopharmaceutical company plunged 31% in after-hours trading.

Magenta Therapeutics Inc. said it paused dosing in a clinical trial of MGTA-117 after a participant died in a possible connection to the treatment. The trial targets blood and bone marrow tumors. Shares of the biotechnology company fell 25% in after-horus trading.

Las Vegas Sands Corp. reported an 11% boost to its fourth-quarter revenue and offered an optimistic view for 2023. Chief Executive Robert Goldstein said he is confident that travel and tourism spending will continue to recover this year. Shares rose 4.2% in after-hours trading.

Seagate Technology Holdings PLC posted fiscal second-quarter results that beat analysts’ expectations and guided for higher-than-anticipated revenue for the third quarter. Shares of the data storage company climbed 7.6% in after-hours trading.

Write to Sabela Ojea at [email protected]; @sabelaojeaguix

.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button